普鲁碘胺 | 123-47-7

• 物质功能分类: 原料药 - 专科用药 - 眼科用药
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 普鲁碘胺
• 中文别名: 普罗碘铵；安妥碘
• 英文名称: Prolonium iodide
• 英文别名: [2-hydroxy-3-(trimethylazaniumyl)propyl]-trimethylazanium;diiodide
• CAS: 123-47-7
• 化学式: C9H24I2N2O
• 分子量: 430.11
• InChiKey: UOZDOLIXBYLRAC-UHFFFAOYSA-L

物化性质

• 熔点：
  ~275° with decompn
• LogP：
  -3.633 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.23
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• WGK Germany：
  3
• 安全说明：
  S24/25,S26,S36
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

用途：眼科用药。

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• BIOZEMENTIERUNGSMISCHUNG
  申请人：DUST BIOSOLUTIONS GMBH

  公开号：EP3736254A1

  公开（公告）日：2020-11-11

  Die vorliegende Erfindung betrifft primär eine Mischung, die zur Biozementierung in der Lage ist.

  本发明主要涉及一种能够进行生物降解的混合物。
• Agent with a retarded release of substances
  申请人：Beisel Gunther

  公开号：US20060141007A1

  公开（公告）日：2006-06-29

  The present invention relates to a composition for producing a satiation effect and for weight reduction comprising at least one compound which is swellable and comprises nutrients.

  本发明涉及一种用于产生饱腹感和减轻体重的组合物，其中包含至少一种可膨胀并含有营养成分的化合物。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.